NEWS ANNOUNCEMENT
FOR IMMEDIATE RELEASE
CONTACT: Robin Baum at 440-392-7428
Robin_baum@steris.com
STERIS CORPORATION ANNOUNCES
COLLABORATIVE ALLIANCE WITH ST. JUDE MEDICAL
FOR ADVANCED CARDIAC LABORATORIES
Cardiovascular laboratories will offer the latest technology and integration for medical
professionals
MENTOR, OHIO – FEBRUARY 27, 2012 – STERIS Corporation (NYSE: STE), a provider of
distinctive surgical support and integration technologies and services, announced today that they will
collaborate with St. Jude Medical, Inc. a global medical device manufacturer, on the planning and
implementation of advanced cardiac laboratories for healthcare providers in the U.S. These labs
feature technologies across the cardiovascular service line for hospitals and clinics interested in
developing state-of-the-art laboratories that meet their changing clinical needs.
STERIS and St. Jude Medical will work together to design and deliver highly integrated
cardiac laboratories. STERIS will assist with the detailed design and planning of the labs and will
contribute their advanced Harmony® LED Surgical Lighting and Visualization System, Harmony
iQ™ High-definition Surgical Integration System and displays, and highly efficient Harmony
equipment management systems. STERIS room design services, including 3-D Room Builder
software and project management expertise, will allow the two companies to seamlessly integrate
their technologies. In addition, the labs may include innovative St. Jude Medical technologies such
as the EnSite Velocity™ Cardiac Mapping System, MediGuide™ Technology, EP-Workmate® Lab
Recording System, ILUMIEN™ PCI Optimization System and a complete portfolio of irrigated
ablation technologies.
These solutions are designed to offer healthcare providers improved coordination of care
through the ability to seamlessly share information and inter-operate across the clinical workflow,
which provides a simplified solution that supports efficient delivery of care.
Press Release/ STERIS Corporation Announces Collaboration with St. Jude Medical
Page 1 of 3
"The relationship we have with St. Jude Medical is a pioneering collaboration, and the
opportunity it offers to healthcare providers on the electrophysiology (EP) frontier is unique,” said
Bill O’Riordan, vice president and general manager of the STERIS Surgical Solutions Group. “It
allows us to jointly deliver laboratory solutions unlike any others."
Three fully functional labs located at St. Jude Medical facilities in the U.S. are available to
provide training for medical professionals who wish to become proficient with St. Jude Medical and
STERIS technologies, while also demonstrating the benefits these advanced cardiac laboratories
have to offer.
“St. Jude Medical has established a broad and deep product portfolio in electrophysiology,
interventional cardiology and cardiac surgery. By working with STERIS, we are able to further
expand our capabilities to provide lab design solutions to our customers in the U.S.,” said Joel
Becker, president of the St. Jude Medical United States Division. “We are excited to bring together
the expertise of these two companies to offer our customers advanced cardiac labs designed to
enhance efficiency, productivity and workflow across multiple cardiac specialties.”
For more information on these projects, please visit www.sjm.com, and www.steris.com.
About STERIS Corporation
STERIS Corporation is a leading provider of infection prevention and surgical products and services,
focused primarily on critical healthcare, pharmaceutical and research markets around the world. The
Company supplies a broad array of equipment, consumable and service solutions that help assure
productivity and quality. STERIS is listed on the New York Stock Exchange under the symbol STE.
This news release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forwardlooking information affecting or relating to the Company or its industry that are intended to qualify for the protections
afforded "forward- looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and
regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects,"
"targets," "forecasts," and "seeks," or the negative of such terms or other variations on such terms or comparable
terminology. Many important factors could cause actual results to differ materially from those in the forward-looking
statements including, without limitation, disruption of production or supplies, changes in market conditions, political
events, pending or future claims or litigation, competitive factors, technology advances, and changes in government
regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K
and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be
provided as to any future financial results. Unless legally required, the Company does not undertake to update or revise
any forward-looking statements even if events make clear that any projected results, express or implied, will not be
realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the
Press Release/ STERIS Corporation Announces Collaboration with St. Jude Medical
Page 2 of 3
forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to
erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or
applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated,
(c) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other
requirements or standards may delay or prevent new product introductions, affect the production and marketing of
existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or
effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or
other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand,
for the Company's products and services, and (f) the possibility that product launch and other expenses may be greater or
customer acceptance of the product may not be achieved, or that, labor, competition, timing, execution, regulatory,
governmental, or other issues or risks associated with the matters described in this release may adversely impact
Company performance, results, or value.
###
Press Release/ STERIS Corporation Announces Collaboration with St. Jude Medical
Page 3 of 3